Natera, Inc. (NTRA) Q2 2026 Earnings Call Transcript

Natera, Inc. ( NTRA ) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDT Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - CEO & Director Solomon Moshkevich - President of Clinical Diagnostics Alexey Aleshin - GM of Oncology and Early Cancer Detection & Chief Medical Officer Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division Daniel Brennan - TD Cowen, Research Division David Westenberg - Piper Sandler & Co., Research Division Daniel Markowitz - Evercore ISI Institutional Equities, Research Division Noah Kava - Jefferies LLC, Research Division Kallum Titchmarsh - Morgan Stanley, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Hello, everyone. Thank you for joining us, and welcome to Natera's Second Quarter 2026 Earnings Conference Call. I will now hand the conference over to Michael Brophy, Chief Financial Officer. Mike Brophy Chief Financial Officer Thanks, operator. Good afternoon. Thank you for joining our conference call to discuss the results of our second quarter of 2026. On the line, I'm joined by Steve Chapman, our CEO; Solomon Moshkevich, President, Clinical Diagnostics; and Alexey Aleshin, General Manager of Oncology and our Chief Medical Officer. Today's conference call is being broadcast live via webcast. We will be referring to a slide presentation that has been posted to investor.natera.com. A replay of the call will also be posted to our IR site as soon as it's available. Starting on Slide 2. During the course of this conference call, we will make forward-looking statements regarding future events and our anticipated future performance, such as our operational and financial outlook and projections, our assumptions for that outlook, market size, partnerships, clinical studies and expected results, opportunities and strategies and expectations for various current and future products, including product capabilities, expected release dates, reimbursement coverage and related effects on our financial and operating results. We caution you that such statements reflect